NCT07638722

Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-10-03Est. Completion: 2028-07-31

Enrollment target: 138 participants

Other microbiome trials you might be interested in

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersPhase 2Recruiting

Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesPrecancerous/Nonmalignant Condition

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the …

Multiple LocationsEst. completion Mar 13, 2007

View Trial →

Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell LymphomaRecruiting

Indolent Lymphoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.